(Q46036078)

18 December 2017

title

Phase I study of the effect of gastric acid pH modulators on the bioavailability of oral dasatinib in healthy subjects. (English)

1 reference

18 December 2017

main subject

dasatinib monohydrate

1 reference

1 reference

1 reference

Timothy Eley

1

1 reference

18 December 2017

Feng R Luo

2

1 reference

18 December 2017

Shruti Agrawal

3

1 reference

18 December 2017

Ashish Sanil

4

1 reference

18 December 2017

James Manning

5

1 reference

18 December 2017

Tong Li

6

1 reference

18 December 2017

Anne Blackwood-Chirchir

7

1 reference

18 December 2017

Richard Bertz

8

1 reference

18 December 2017

publication date

24 April 2009

1 reference

18 December 2017

The Journal of Clinical Pharmacology

published in

1 reference

18 December 2017

volume

49

1 reference

18 December 2017

issue

6

1 reference

18 December 2017

page(s)

700-709

1 reference

18 December 2017

Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0091270009333854

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009333854

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009333854

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009333854

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009333854

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009333854

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009333854

High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009333854

BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009333854

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009333854

The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009333854

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009333854

Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009333854

Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009333854

Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009333854

Metabolism and disposition of dasatinib after oral administration to humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009333854

Antacids revisited: a review of their clinical pharmacology and recommended therapeutic use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009333854

Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009333854

21 January 2018

Identifiers

DOI

10.1177/0091270009333854

1 reference

18 December 2017

PubMed ID

19395585

1 reference

18 December 2017